470
Participants
Start Date
July 31, 2003
Primary Completion Date
March 31, 2010
Study Completion Date
March 31, 2010
capecitabine (Xeloda®)
825 mg/m\^2 or 1250 mg/m2 orally twice a day on days 1 to 14 of each 3 week cycle.
docetaxel (Taxotere®)
75 mg/m\^2 intravenous on day 1 of each 3 week cycle
Durban
Bloemfontein
Bangkok
Williamsville
Allentown
Kingston
Baltimore
Baltimore
Frederick
Abingdon
Columbia
Charleston
Jacksonville
Miami Shores
Fort Lauderdale
Tamarac
Boca Raton
Inverness
Port Saint Lucie
Hoover
Birmingham
Knoxville
Collierville
Khon Kaen
Mayfield Heights
Canton
Beech Grove
Kalamazoo
Chiang Mai
Des Moines
Skokie
Urbana
Saint Joseph
Jefferson City
Overland Park
Houma
Sarajevo
Tuzla
Houston
Austin
Tucson
Mostar
Poway
Berkeley
Walla Walla
Beijing
Beijing
Moscow
New Delhi
Moscow
Dalian
Dalian
Yaroslavl
Ivanovo
Saint Petersburg
Saint Petersburg
Shanghai
Bengbu
Tianjin
Jaipur
Hangzhou
Ryazan
Mumbai
Kazan'
Kazan'
Samara
Chelyabinsk
Bangalore
Omsk
Rockville
Boston
Detroit
Paramus
Summit
Colchester
Pardubice
Prague
Prague
Prague
Tábor
Ahmedabad
Bangalore
Hyderabad
Hyderabad
Hyderabad
Kochi
Kolkata
Ludhiana
Manipal
Trivandrum
Vellore
Poznan
Wroclaw
Polokwane
Hoffmann-La Roche
INDUSTRY